Cibc Asset Management Inc Vertex Pharmaceuticals Inc Transaction History

Cibc Asset Management Inc

$28.3 Billion
Q3 2024

A detailed history of Cibc Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cibc Asset Management Inc holds 80,102 shares of VRTX stock, worth $37.2 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

80,102

Previous 75,670 5.86%

Holding current value

$37.2 Million

Previous $35.5 Million 5.03%

% of portfolio

0.13%

Previous 0.14%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$460.0 - $505.78 $2.04 Million - $2.24 Million	4,432 Added 5.86%	80,102 $37.3 Million
Q2 2024 Aug 01, 2024	SELL	$392.81 - $485.53 $264,753 - $327,247	-674 Reduced 0.88%	75,670 $35.5 Million
Q1 2024 May 09, 2024	BUY	$407.69 - $446.08 $1.73 Million - $1.89 Million	4,236 Added 5.87%	76,344 $31.9 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $2,401 - $2,874	7 Added 0.01%	72,108 $29.3 Million
Q3 2023 Oct 30, 2023	BUY	$338.18 - $362.46 $2.42 Million - $2.6 Million	7,169 Added 11.04%	72,101 $25.1 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $118,221 - $132,318	-376 Reduced 0.58%	64,932 $22.9 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $239,895 - $273,665	847 Added 1.31%	65,308 $20.6 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $450,643 - $506,973	-1,577 Reduced 2.39%	64,461 $18.6 Million
Q3 2022 Nov 03, 2022	BUY	$273.83 - $305.53 $852,980 - $951,725	3,115 Added 4.95%	66,038 $19.1 Million
Q2 2022 Aug 09, 2022	SELL	$234.96 - $292.55 $1.1 Million - $1.36 Million	-4,664 Reduced 6.9%	62,923 $17.7 Million
Q1 2022 May 06, 2022	SELL	$221.42 - $260.97 $12,178 - $14,353	-55 Reduced 0.08%	67,587 $17.6 Million
Q4 2021 Feb 08, 2022	BUY	$177.01 - $223.45 $1.12 Million - $1.41 Million	6,305 Added 10.28%	67,642 $14.9 Million
Q3 2021 Nov 09, 2021	BUY	$181.39 - $202.99 $745,331 - $834,085	4,109 Added 7.18%	61,337 $11.1 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $504,348 - $594,759	2,690 Added 4.93%	57,228 $11.5 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $1.44 Million - $1.68 Million	6,965 Added 14.64%	54,538 $11.7 Million
Q4 2020 Feb 03, 2021	BUY	$207.01 - $276.09 $625,377 - $834,067	3,021 Added 6.78%	47,573 $11.2 Million
Q3 2020 Nov 05, 2020	BUY	$255.65 - $303.1 $1.54 Million - $1.83 Million	6,032 Added 15.66%	44,552 $12.1 Million
Q2 2020 Jul 28, 2020	BUY	$225.48 - $295.8 $257,949 - $338,395	1,144 Added 3.06%	38,520 $11.2 Million
Q1 2020 Apr 30, 2020	BUY	$199.77 - $247.81 $132,647 - $164,545	664 Added 1.81%	37,376 $8.89 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $236,894 - $318,176	1,421 Added 4.03%	36,712 $8.04 Million
Q3 2019 Oct 30, 2019	SELL	$166.23 - $187.09 $30,420 - $34,237	-183 Reduced 0.52%	35,291 $5.98 Million
Q2 2019 Aug 05, 2019	BUY	$164.61 - $190.37 $162,470 - $187,895	987 Added 2.86%	35,474 $6.51 Million
Q1 2019 May 06, 2019	SELL	$163.73 - $194.7 $3,602 - $4,283	-22 Reduced 0.06%	34,487 $6.34 Million
Q4 2018 Feb 12, 2019	BUY	$151.91 - $192.21 $91,297 - $115,518	601 Added 1.77%	34,509 $5.72 Million
Q3 2018 Nov 02, 2018	BUY	$167.73 - $192.74 $105,166 - $120,847	627 Added 1.88%	33,908 $6.54 Million
Q2 2018 Aug 09, 2018	BUY	$145.72 - $169.96 $289,399 - $337,540	1,986 Added 6.35%	33,281 $5.66 Million
Q1 2018 Apr 30, 2018	SELL	$151.6 - $177.13 $37,445 - $43,751	-247 Reduced 0.78%	31,295 $5.1 Million
Q4 2017 Feb 02, 2018	SELL	$137.28 - $155.55 $42,556 - $48,220	-310 Reduced 0.97%	31,542 $4.73 Million
Q3 2017 Nov 06, 2017	BUY	$148.13 - $162.24 $4.72 Million - $5.17 Million	31,852	31,852 $4.84 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Account

Cibc Asset Management Inc Vertex Pharmaceuticals Inc Transaction History